VANCOUVER, Jan. 7 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leader
in advancing novel, targeted protein toxin therapeutics for the treatment of
cancer and other proliferative diseases, announced today that it has appointed
Mr. Tom D'Orazio as Vice President, Business Development and Strategy.
Mr. D'Orazio is a pharmaceutical executive who brings nineteen years of
industry experience to Protox. His past responsibilities include management of
commercial partnerships, strategic marketing, pipeline valuation and strategic
planning. Most recently he was employed as Vice President of Strategic
Marketing at Sonus Pharmaceuticals where he managed the commercial
relationship with the oncology unit of Bayer Schering AG. He also was in
charge of the commercial planning for Sonus' entire pipeline of clinical-stage
and pre-clinical oncology products. Prior to his employment with Sonus, Mr.
D'Orazio spent five years with QLT managing their global marketing
relationship with Novartis, and as the commercial lead on their oncology and
ocular in-licensing teams. Mr. D'Orazio came to QLT after spending six years
at Pharmacia's (now Pfizer) global headquarters where he was instrumental in
planning the launch of a new business unit that had responsibility for a
portfolio of products for pituitary tumors and related neuroendocrine
diseases. Mr. D'Orazio's first experience in oncology dates back seventeen
years to when he was employed by Immunex (now Amgen). He holds a bachelors
degree in Chemistry from Loyola University of Chicago and an M.B.A. from
"This strategic appointment is a key and timely addition to our team as
we enter into multiple later stage clinical programs," said Dr. Fahar
Merchant, President & CEO of the Company. "Tom brings a wealth of business
development experience to Protox and will be ideally suited to explore and
build upon a number of key commercial relationships."
Protox Therapeutics is a leader in advancing novel, targeted protein
toxin therapeutics for the treatment of cancer and other proliferative
diseases. Two novel drug candidates derived from the company's INxin(TM) and
PORxin(TM) platforms are being developed in three clinical programs. A Phase
2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain
cancer has been completed and the drug has received Fast Track Designation and
Orphan Drug Status from the US FDA. Phase 1 clinical trials evaluating PRX302
(PORxin) have been completed for the treatment of localized prostate cancer
and benign prostatic hyperplasia (enlarged prostate).
NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS
RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
For further information:
For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 484-0975, email@example.com; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,